ESMO Congress | Conference

Sintilimab Improves OS in Advanced ESCC, Gastric/GEJ Cancer

September 17th 2021

Findings from a pair of studies presented at the 2021 European Society for Medical Oncology Annual Meeting showed that adding sintilimab to chemotherapy significantly improved overall survival compared with chemotherapy alone in patients with unresectable, locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma and those with unresectable, locally advanced, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma.

Erdafitinib Plus Cetrelimab Exhibits Encouraging Efficacy in Metastatic Urothelial Cancer

September 17th 2021

Erdafitinib in combination with cetrelimab displayed clinically meaningful responses in patients with metastatic or locally advanced urothelial carcinoma harboring FGFR alterations.

Nivolumab/Cabozantinib Combo Yields Efficacy Regardless of Prior Nephrectomy in RCC

September 17th 2021

Nivolumab and cabozantinib demonstrated significant benefits in progression-free survival and objective response rate for patients with renal cell carcinoma regardless of whether they had a prior nephrectomy.

Nivolumab/Chemo Approaches EU Approval for Select HER2– Advanced or Metastatic Gastric, GEJ, or Esophageal Adenocarcinoma

September 17th 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of nivolumab plus fluoropyrimidine and platinum-containing chemotherapy as frontline treatment for adult patients with HER2-negative advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma with a PD-L1 combined positive score of 5 or higher.

VHL-Mutated and VHL Wild-Type Clear Cell RCC May Present Similar Clinical Characteristics

September 17th 2021

Similarities in clinical characteristics in these patients despite differences in other genomic alterations may impact potential clinical trial treatment selection.

Improved Communication Needed for Patients With RCC Subtype

September 17th 2021

Patients with renal cell carcinoma and their families may have a lack of understanding about the disease, clinical trials, and psychosocial impact.

Brigatinib Maintains Superior PFS Benefit Over Crizotinib With High Intracranial Efficacy in ALK+ NSCLC

September 16th 2021

Brigatinib resulted in a 52% reduction in the risk of disease progression or death and a 56% reduction in the risk of intracranial progression compared with crizotinib in patients with ALK-positive non–small cell lung cancer, according to final data from the phase 3 ALTA-1L trial.

Global Maximum-Tolerated Dose of Mobocertinib Found Tolerable in Japanese Patients With NSCLC

September 16th 2021

Mobocertinib displayed a manageable safety profile across 40-mg, 120-mg, and 160-mg dose cohorts in Japanese patients with non–small cell lung cancer, which, when coupled with pharmacokinetic analysis, led to the determination of 160 mg as the maximum tolerated dose and recommended phase 2 dose for further study in this population.

Mobocertinib Shows Improved Responses Vs Real-World Data in Advanced EGFR Exon 20 Insertion+ NSCLC

September 16th 2021

Mobocertinib, a novel EGFR tyrosine kinase inhibitor, exhibited clinically meaningful activity in patients with non–small cell lung cancer who harbor EGFR exon 20 insertion mutations following frontline platinum-based chemotherapy when compared indirectly with real-world data of patients treated with standard of care.

Linagliptin/Atezolizumab Combo Shows Limited Clinical Activity in Second-Line Gastric/GEJ Cancer

September 16th 2021

Linagliptin plus atezolizumab was linked with limited responses as a second-line treatment for patients with locally advanced or metastatic gastric or gastroesophageal junction cancer who participated in an arm of the open-label, phase 1b/2 MORPHEUS platform.

TMB-H Status Linked With High Responses to Dostarlimab in Endometrial Cancer

September 16th 2021

Patients with endometrial cancer who had a high tumor mutational burden experienced high responses to single-agent dostarlimab-gxly, irrespective of mismatch repair or microsatellite stability status.

Darolutamide Plus ADT Demonstrates Similar Safety Profile Vs ADT Alone in Nonmetastatic CRPC

September 16th 2021

The safety profile of daralutamide in combination with androgen-deprivation therapy was similar to placebo in patients with nonmetastatic castration-resistant prostate cancer.

Darolutamide Favorably Affects Episodic Memory Vs Enzalutamide in mCRPC

September 16th 2021

Treatment with darolutamide was associated with statistically significant benefits in episodic memory by computerized cognitive assessment compared with enzalutamide in patients with metastatic castration-resistant prostate cancer.

ESMO 2021: Oncology Experts Share Game-Changing Data in Breast Cancer, Gynecologic Malignancies

September 16th 2021

The 2021 ESMO Congress, held as a virtual format for the second consecutive year, is fast approaching and isn’t holding back in terms of pivotal data across malignancies, especially in breast cancer and gynecologic cancers.

Brigatinib Boosts Intracranial PFS and Health-Related QoL in ALK+ NSCLC

October 1st 2020

Brigatinib demonstrated sustained improvements in overall and intracranial progression-free survival and health-related quality of life compared with crizotinib in patients with ALK-positive advanced non–small cell lung cancer.

Plinabulin Shows Efficacy in Chemo-Induced Neutropenia Prevention During COVID-19 Era

September 29th 2020

Plinabulin was found to be a more favorable option for the prevention of chemotherapy-induced neutropenia compared with pegfilgrastim during the coronavirus disease 2019 pandemic.

Apalutamide Maintains Health-Related QoL Among Men With Nonmetastatic CRPC

September 25th 2020

With more than 4 years of follow-up, the health-related quality of life of men with nonmetastatic castration-resistant prostate cancer receiving androgen deprivation therapy was shown to be maintained with the addition of apalutamide.

Dr. Nixon on the Role of MSI in Cancer

September 24th 2020

Andrew B. Nixon, PhD, MBA, discusses the role of microsatellite instability in cancer.

Dr. Grivas on the Subgroup Analyses of the JAVELIN Bladder 100 Trial in Advanced Urothelial Cancer

September 24th 2020

Petros Grivas, MD, PhD, discusses findings from the subgroup analyses of JAVELIN Bladder 100 in advanced urothelial cancer.

Dr. Bardia on the Need to Develop Additional Therapies in Metastatic TNBC

September 24th 2020

Aditya Bardia, MD, MPH, discusses the need to develop additional therapies for patients with metastatic triple-negative breast cancer.